Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Operating Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Operating Leases for 8 consecutive years, with $65.6 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases fell 7.86% year-over-year to $65.6 million; the TTM value through Mar 2026 reached $65.6 million, down 7.86%, while the annual FY2025 figure was $67.0 million, 7.44% down from the prior year.
  • Operating Leases hit $65.6 million in Q1 2026 for Kymera Therapeutics, down from $67.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $77.0 million in Q4 2023 and bottomed at $12.1 million in Q4 2022.
  • Average Operating Leases over 5 years is $57.5 million, with a median of $69.8 million recorded in 2025.
  • Year-over-year, Operating Leases decreased 8.15% in 2022 and then surged 534.18% in 2023.
  • Kymera Therapeutics' Operating Leases stood at $12.1 million in 2022, then soared by 534.18% to $77.0 million in 2023, then fell by 5.98% to $72.4 million in 2024, then fell by 7.44% to $67.0 million in 2025, then decreased by 2.16% to $65.6 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $65.6 million, $67.0 million, and $68.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.